151 related articles for article (PubMed ID: 24787970)
1. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
Azad AA; Jones EC; Chi KN
Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
[No Abstract] [Full Text] [Related]
2. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
3. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy.
Patel R; Faiena I; Geltzeiler J
Can J Urol; 2015 Apr; 22(2):7752-4. PubMed ID: 25891342
[TBL] [Abstract][Full Text] [Related]
4. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy in the management of neuroendocrine prostate cancer.
Martínez-Cornelio A; González-Pérez J; Tabares-García Fde J; Ramos-Salgado F; Alvarado-Cabrero I; Hernández-Toriz N
Cir Cir; 2009; 77(4):293-9; 273-8. PubMed ID: 19919791
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
[TBL] [Abstract][Full Text] [Related]
7. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
[TBL] [Abstract][Full Text] [Related]
8. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
9. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
11. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy.
Embry JR; Kelly MG; Post MD; Spillman MA
Gynecol Oncol; 2011 Mar; 120(3):444-8. PubMed ID: 21138780
[TBL] [Abstract][Full Text] [Related]
12. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
13. Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan.
Tzou KY; Cheng WH; Lee WH; Ho CH
J Cancer Res Ther; 2018 Sep; 14(Supplement):S785-S788. PubMed ID: 30249904
[TBL] [Abstract][Full Text] [Related]
14. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
15. [A case of large cell neuroendocrine carcinoma of the stomach with liver metastasis effectively treated with S-1 and CDDP combination therapy].
Fujimura Y; Nakahara O; Otao R; Goto H; Baba H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):369-71. PubMed ID: 24743286
[TBL] [Abstract][Full Text] [Related]
16. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
Williams S; Buyyounouski M; Kestin L; Duchesne G; Pickles T
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):724-31. PubMed ID: 20472361
[TBL] [Abstract][Full Text] [Related]
17. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
18. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Huang CY; Pu YS; Yu CC; Huang CH
Prostate; 2011 Aug; 71(11):1189-97. PubMed ID: 21656829
[TBL] [Abstract][Full Text] [Related]
19. [Aspects for hormone therapy in prostate cancer].
Gorski J; Böhm WD; Kelly LU
Z Urol Nephrol; 1981 Sep; 74(9):635-41. PubMed ID: 7314984
[TBL] [Abstract][Full Text] [Related]
20. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
Filosso PL; Ruffini E; Oliaro A; Rena O; Casadio C; Mancuso M; Turello D; Cristofori RC; Maggi G
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):819-24. PubMed ID: 15821649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
